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The aqueous extract of the Argentinean native plant, Prosopis strombulifera (PsAE), presents cytotoxicity against
human cancer cell lines by inducing cytostasis, necrosis and apoptosis; with diminution of clonogenic survival;
without genotoxic effects nor oral animal toxicity. Until now, the chemical extract composition and its in vivo
antitumoral properties remain unknown; these studies are the aim of the current work. The PsAE was charac-
terized by chemical fingerprinting and the metabolome was identified by tandem UHPLC-PDA-HESI-Q-orbitrap®
mass spectrometry. Colorectal tumors were induced by DMH administration and melanomas resulted from B16-F0
S.C. cells injection; then, animals were treated orally with PsEA. To correlate in vivo results with in vitro cyto-
toxicity, B16-F0 cell were cultured to determine: cell proliferation and viability by dye exclusion assays, MTT and
CFSE dilution; cell cycle distribution by flow cytometry; and immunoblotting of p21cip1, PCNA, cleaved caspase 3,
cleaved PARP and TUBA1A. Based on UHPLC-OT-MS and PDA analysis, twenty-six compounds were identified,
including: 5 simple organic acids, 4 phenolic acids, 4 procyanidins, 11 flavonoids, and 2 oxylipins. On C57BL6
mice, PsAE significantly increases the median survival on colorectal cancer and reduces the final volume and
weight of melanomas. Over cultured cells, the treatment induce over-expression of p21, cytostasis by G2/M cell
cycle arrest and apoptosis; while, on in vivo melanomas, treatment up-regulates p21 and slightly decreases PCNA.
In conclusion, PsAE is composed by phenolic compounds which demonstrate cytotoxic and antitumoral properties
when is orally administrated. Presented results support future research of PsAE as a potential phytomedicine for
cancer treatment.1. Introduction
Cancer consist of a group of illness with a common feature of un-
controlled cellular proliferation determined by several genetic, epige-
netic and biochemical causes (Moreno-Sanchez et al., 2014). Despite ofGamarra-Luques).
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is an open access article under tthe many improvements obtained in cancer treatment, additional an-
swers need to be found to overlap the remained deficiencies. Chemo-
therapy, as well as conventional treatments against cancer, usually
determine unfavorable collateral effects and fails to control cancer pro-
gression. The utilization of medicinal plants were proposed as an option0 January 2020
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significant reduction in the undesired effects present in cancer treatment,
may be achieved by the use of plant-derived products, among others
natural therapies. If well, many anticancer agents were originally
described from plants, there are many sources which remain not
completely explored (Sultana et al., 2014). In a wide range of climate,
Argentina has an abundant and diverse flora. Despite of this, the me-
dicinal properties of native plants were not sufficiently explored;
particularly, in relation to cancer. Until now, there are only a few sci-
entific reports about plant antitumoral activities (Mamone et al., 2011).
Prosopis strombulifera (Lam.) Benth, from the Fabaceae family, is a
rhizomatous shrub which grows up to 1.5 m height in Argentina,
northern and central zones. Locally known as “retortu~no”, the plant
has been ethnopharmacologically used as an astringent, odontalgic, to
treat inflammation and diarrhea; scientifically, its anti-bacterial and
anti-nociceptive properties have been described. Beneficial biomedical
properties of genus Prosopis were summarized by Persia et al. (2016).
In relation to cancer, P. strombulifera aqueous extract (PsAE) has
demonstrated in vitro cytotoxic activity against colorectal and mam-
mary adenocarcinoma cancer cell lines (HCT-116 and MCF-7, respec-
tively) by induction of cytostasis, necrosis and apoptosis; with
significant diminution in clonogenic survival at LC50 doses. By the
Ames' test, genotoxic effects of treatment were discarded at the cyto-
toxic doses used. Moreover, in a BALB/c mice model, no toxicity was
evidenced at doses up to 150 mg/animal/day when orally adminis-
trated (Hapon et al., 2014).
We hypothesized that PsAE is composed of potential cytotoxic com-
pounds that are able to induce antitumoral effects when are orally
administrated. To promote PsAE as a plant-derived compound related to
cancer, the objective of this work is to characterize the aqueous extract
composition by UHPLC-Q-OT-HESI-MS/MS and to demonstrate its in vivo
antitumoral properties in mice allograft models of colorectal and mela-
noma cancers. Additionally, the molecular intermediates of cytotoxic and
antitumoral effects were also evaluated.Figure 1. UHPLC-Q-OT-HESI-MS/MS fingerprints of PsAE. A. The total Ion
2
2. Results and discussion
2.1. UHPLC-Q-OT-HESI-MS/MS analysis of PsAE
The hyphenated chromatographic-spectrometric study of PsAE
allowed the detection of 29 peaks (Figures 1A and 1B), where identifi-
cation of 26 compounds was possible, including: 5 simple organic acids, 4
phenolic acids, 4 procyanidins, 11 flavonoids, and 2 oxylipins (Table 1).
The full metabolome identification is explained below:
Simple organic acids: xylonic, citric, isocitric, grisenilosidic and
tuberonic acid glucoside; peaks 2-4, 12 and 14, respectively.
Phenolic acids: protocatechuic, piscidic, salicylic and marmesin;
peaks 6, 7, 24 and 29, respectively.
Procyanidins: flavanols gallocatechin and epigallocatechin, catchin
and procyanidin B1; peaks 8, 11, 13 and 15, respectively.
Flavonoids: daidzein 7-O-glucuronide, neoeriocitrin, kaempferol 3-O-
neohesperidose, myricitrin 3-O-glucoside, rhoifolin, rutin, kaempferol
glucoside, kaempferol rhamnoside, naringoside, formononetin 7-O-
6acetylglucoside, kaempferol; peaks 5, 9, 10, 16-22 and 25, respectively.
Some compounds were identified as flavanones (l max 281 nm), other as
isoflavones (l max 281 nm) and other as flavonols (l max 254–354 nm).
Oxylipins: unsaturated fatty acids trihydroxylinoleic acid and trihy-
droxyoctaenoic acid; peaks 26 and 28, respectively.
The chemical characterization of PsAE, identified 26 compounds; at
least, 12 of them had been previously reported as cytotoxic. While,
protocatechuic acid (Tsao et al., 2014), marmesin (Dong et al., 2018),
rutin (Asfour and Mohsen, 2017), kaempferol, kaempferol glucoside and
kaempferol rhamanoside (Wang et al., 2018) were described as isolate
active compounds against cancer cells; citric acid, gallocatechin, epi-
gallocatechin, procyanidin B and rhoifolin were reported as component
of natural extracts with cytotoxic activity (Koyuncu, 2018; Navarro et al.,
2017; Radan et al., 2017; Tremocoldi et al., 2018). The concurrence of
the mentioned compounds into PsAE ensures its anticancer effects and
promotes new research concerning its biological properties.Current (TIC) chromatogram. B. The UV-vischromatogram at 330 nm.
















1 1.87 - Unknown 272.95877
2 2.11 - Xylonic acid C6H8O7- 165.03984 165.03936 2.88
3 2.41 - Citric acid C6H8O7- 191.01932 191.01863 3.44
4 2.86 - Citric acid isomer C6H8O7- 191.01929 191.01863 3.44
5 5.29 280 Daidzein 7-O-glucuronide C21H17O10- 429.08162 429.08270 2.51
6 6.50 305-350 Protocatechuic acid C7H5O4- 153.01868 153.01824 2.88
7 7.69 271 Piscidic acid C11H11O7- 255.05090 255.04993 3.81
8 8.08 271 Gallocatechin C15H13O7- 305.06671 305.06558 3.71 289.07169 (catechin)
9 9.90 281 Neoeriocitrin (eriodictyol 7 neohesperidoside) C27H31O15- 595.16614 595.16575 0.65
10 10.03 255-365 Kaempferol 3-O-neohesperidose C30H25O13- 593.12952 593.12897 0.92 285.0610 (kaempferol)
11 10.36 271 Epigallocatechin C15H13O7- 305.06674 305.06558 3.81 289.07169 (catechin)
12 10.55 295-345 Grisenilosidic acid C17H21O12- 417.10379 417.10275 2.46 177.01866
13 10.77 271 Catechin C15H13O6- 289.07178 289.07066 0.44 125.02163
14 11.14 198 Tuberonic acid glucoside C18H27O9- 387.16496 387.16611 0.48 309.13739, 261.08792
15 11.34 271 Procyanidin B1 C3oH25O12- 577.13434 577.13404 0.48 289.07175 (catechin)
16 11.69 255-355 Myricitrin 3-O-glucoside C17H19O9- 479.08202 479.08307 2.19 271.02454
17 11.81 269 Rhoifolin C27H30O14- 577.15518 577.15570 0.89
18 11.90 255-354 Rutin C27H29O16- 609.14611 609.14532 0.41 271.02472
19 12.21 255-365 Kaempferol glucoside C21H19O11- 447.09320 447.09219 2.26 285.04019 (kaempferol)
20 12.06 270-334 Kaempferol rhamnoside C21H19O10- 431.09833 431.09727 2.44 285.0610 (kaempferol)
21 12.71 255-325 Naringoside C27H31O14- 579.17083 579.17083 2.96
22 13.11 310 Formononetin 7-O-6acetylglucoside C24H23O10- 471.12979 471.12857 2.58
23 13.35 220 Unknown C18H33O5- 341.23837 341.23678 4.67
24 14.47 240 Hydroxybenzoic acid (salicilic acid) C7H6O3- 137.02373 137.02332 2.96
25 15.25 255-365 Kaempferol C34H29O15- 285.04046 285.04053 0.24
26 17.86 220 Trihydroxylinoleic acid C18H31O5- 327.21660 327.21331 3.39
27 16.45 220 Unknowrn C18H33O5- 341.23837 341.23678 4.67
28 17.98 220 Trihydroxyoctaenoic acid C18H33O5- 329.23346 329.23225 3.57
29 19.38 254-354 Marmesin C14H19O4- 245.08173 245.08084 3.63
F.A. Persia et al. Heliyon 6 (2020) e03353Many natural derivatives are actually used to treat chronic diseases
like cancer; these products are selected mainly for safety, availability,
tolerance and its biological activity (Singh, 2007). In general, previous
reports indicate that phytochemicals bring a higher protection acting
combined than isolated (Malongane et al., 2017). Therefore, described
constituents of PsAE support its cytotoxicity, potency and efficiency
against a wide range of cancer cell; and promote their use as phyto-
medical agents.
2.2. Evaluation of antitumoral properties of PsAE on mice
Because in vivo antitumoral properties of PsAE were not previously
reported, to probe the extract capability of interfere with in vivo tumor
progression, the present work shows the extract activity on two different
models of cancer. One of them, are the colorectal tumors induced by the
procarcinogen compound DMH; and the other, are the melanomas
induced by subcutaneous injection of B16-F0 cells. Both are considered
as allograft models of cancer in mice and, in the two cases, treatment was
administrated at the major no toxic doses reported of 150 mg/animal/
day (Hapon et al., 2014).
2.2.1. PsAE antitumoral activity: median survival determination on DMH
induced colorectal cancer
To study the in vivo activity of PsAE against colorectal cancer, tumors
were developed by DMH administration in BALB/c mice. A control group
of animals, without DMH tumor induction, were used. These animals
presented 100% survival during the experimental time (52 weeks),
without any signs of tumor development. On the other hand, all animals
DMH treated evidenced humane endpoints criteria related to colorectal3
cancer growth and were euthanized in consequence. Animals weight loss
during experimental time was always between 5 to 8 %. The euthanasia
criteria presented were anal tumor protrusion or anal bleeding. Necropsy
evidenced colorectal polyps in all DMH treated animals, with no differ-
ences in the number of polyps between control and treated groups (18-24
polyps/animal). The diagnosis of colorectal adenocarcinoma was
confirmed by histology. Kaplan-Meier analysis indicates that PsAE
treated animals show the highest median survival, 34.5 weeks, whereas
values of the not treated group and 5Fu treated were 24 and 27 weeks,
respectively (Figure 2A). Survival differences between PsAE treated an-
imals were significant in relation to the control group (Mantel Cox test, p
< 0.0001) and 5Fu group (Mantel Cox test, p ¼ 0.0030). The presented
data demonstrate that PsAE, orally administrated, interferes with colo-
rectal cancer progression. However, by these experiments, it is not
possible to determine if plant derived active compounds act by hema-
tological (systemic) or intraluminal (topic) ways.
2.2.2. PsAE antitumoral activity: systemic antimelanoma activity in allograft
B16-F0 induced tumors
To investigate whether PsAE acts systemically to prevent melanoma
progression, the extract was administrated orally in drinking water from
day 1–22, after subcutaneous implantation of B16-F0 melanoma cells in
C57BL6wt mice. Two additional groups were added; a control group
without any treatment; and the 5Fu treated group. All animals developed
tumors, which were histologically confirmed. At the end of the experi-
ment, day 22 after cells inoculation, the mean weight and volume of
tumors excised from PsAE treated mice were significantly lower than the
control group (Figure 2B). While control tumors weight was 2.389 
0.605 g, in PsAE group was significantly lower, 0.736  0.190 g (p ¼
Figure 2. PsEA antitumoral effects in colorectal and melanoma tumors. A. Kaplan-Meier analysis of survival proportions in BALB/c mice. Median survival of each
animal group is indicated. B. Weight and volume comparison in C57BL6wt mice allograft melanoma tumors. DMH: Dimethylhydrazine. CoNT: Control no treated. 5Fu:
5-Fluoracile. PsAE: P. strombulifera aqueous extract. *: indicates significant differences between CoNT and PsAE groups (ANOVA, Fisher LSD test, p  0.05).
F.A. Persia et al. Heliyon 6 (2020) e033530.0204). When the final volume was analyzed, controls reach final vol-
umes of 219  47.9 mm3 whereas PsAE treated tumors reached a
significantly diminished volumes of 101.7 20.7 mm3 (p¼ 0.0306). The
5Fu treated group showed a final weight of 0.612  0.50 g and a volume
of 99  27.8 mm3; no significant differences with PsAE values were
found. Altogether, the presented results indicate the capability of PsAE to
interfere with melanoma growth in vivo and demonstrate the systemic
bioavailability of the active plant derived compounds.2.3. In vitro evaluation of PsAE cytotoxic effects
To determine how PsAE exerts its antitumoral activity, B16-F0 mu-
rine melanoma cancer cells were cultured and studied in a dose-response
experimental design.
2.3.1. PsAE induce cytotoxic effects by affection of proliferation and viability
Cell number and viability were quantified by dye exclusion assay with
trypan blue, after 48 h of treatment. In vitro activity was quantified by
IC50 and LC50 determination, the chemotherapeutic agent 5Fu was used
as positive control. For PsAE, the estimated IC50 was 2.44  0.18 μg/ml
and the LC50 was 9.01  0.22 μg/ml; whereas the calculated values for
5Fu were 0.12  0.01 and 18.40  1.04 μg/ml, respectively (Figures 3A
and 3B). The obtained results evidence the capability of the PsAE to
induce cytotoxicity in a dose-response manner by affection of cells pro-
liferation and viability.
Next, we examined the morphological features in fixed and stained
B16-F0 cells, 48 h treated, with IC50 and LC50 PsAE concentrations (2.4
and 9 μg/ml, respectively), in comparison with not-treated controls. The
extract reduced cell density, caused rounding nucleus and enlarged cell4
cytoplasms; all changes were evident in a dose-response manner
(Figure 3C).
To confirm the effects induced by PsAE treatment in cell proliferation
two additional techniques were applied. By assessing cell metabolic ac-
tivity with the MTT assay, we demonstrate how increased doses of PsAE
induce growth inhibition in a dose-response manner (Figure 4A). In fact,
the changes determined by quantification of the mitochondrial activity
with PsAE and 5Fu, were able to induce the same proliferative changes to
those calculated by the dye exclusion assay.
In addition, cell proliferation was studied by CFSE dilution in control
and treated cells. Figures 4B, 4C and 4D show how CFSE fluorescence in
control no treated cells (CoNT) results diminished in successive mitotic
divisions. Similarly as was observed in dye exclusion and MTT assays,
PsAE and 5Fu, used at IC50 and LC50 concentrations, interfere with
normal cell division evidenced by increased CFSE fluorescence after 48 h
of treatment (Figures 4B, 4C and 4D).
2.3.2. PsAE induce G2/M cell cycle arrest
To elucidate how PsAE effects the cell cycle progression, we assessed
cell cycle distribution by flow cytometry analysis in B16-F0 cells
(Figures 5A and 5B). Cells were incubated in the presence of PsAE for 24
h at IC50 and LC50 concentrations (2.4 and 9 μg/ml, respectively), un-
treated control cells were also assayed. As shown in Figure 5, treatment
with PsAE induced a marked G2/M arrest with a concurrent reduction of
cell population on G1 in both treated groups. Also, at the IC50 concen-
tration was observed an augmentation of >4N fraction, which represents
cells with higher DNA content than tetraploid cells. Moreover, a slight
increase in hypo-diploid DNA content (SubG1 phase) was observed at
LC50 concentration; which indicates apoptosis as a cell death mechanism
Figure 3. Determination of in vitro PsAE cytotoxic effects. A. Dye exclusion assay of in vitro B16-F0 cell line after 48 h treatment with PsAE in a dose-response
experimental design. B. Proliferation and viability changes induced by 5Fu on B16-F0 cells. C. Morphological changes induced by PsAE treatment at IC50 and LC50
(2.4 and 9 μg/ml, respectively) concentrations compared with not-treated control cells. Size bar corresponds to 50μm. In A and B, IC50 and LC50 were statistically
calculated by a sigmoidal dose-response analysis using Prism® 6.0.
F.A. Persia et al. Heliyon 6 (2020) e03353involved (Gamarra-Luques et al., 2012). Presented results demonstrated
that PsAE interferes with cell cycle progression mainly by the arrest in
G2/M phase and augmentation of >4N cells DNA content; these
mentioned cell cycle distribution changes are similar to compounds
which exert cytotoxicity by mitosis interference (Doleckova et al., 2012;
Liu et al., 2016; Yu et al., 2017; Zhao et al., 2019).
2.3.3. PsAE induce changes in protein expression related to the presence of
cytostasis and apoptosis
Protein expression was determined to study the cytostatic and lethal
effects of PsAE on B16-F0 cultured cells (Figs. 6A and 6B). Three inde-
pendent assays, after 24 h of treatment at 0 μg/ml, IC50 and LC50 PsAE
concentrations (2.4 and 9 μg/ml, respectively), were done. In IC50 treated
cells, in respect to control not-treated cells (CoNT), the cyclin-dependent
kinase inhibitor p21cip1 (p21) significantly increases (p ¼ 0.0273), and
cleaved caspase 3 increases significantly (p ¼ 0.0500); these results are
consistent with cell cycle arrest associated with growth inhibition. At
lethal doses, compared with controls, the expression of p21 was
increased (p ¼ 0.0489), cleaved caspase 3 was significantly increased5
(0.0007); also, detection of cleavage in poly ADP ribose polymerase
(cPARP) revealed the presence of apoptosis and its overexpression
showed a significant increase (p¼ 0.0081); while PCNAwas significantly
reduced (p ¼ 0.0395). Altogether, molecular markers indicate that
cytostasis and lethality are induced in vitro by PsAE treatment mediated
by a p21 related mechanism.
2.4. Molecular confirmation of PsAE antitumoral systemic effects
To correlate the molecular changes evidenced in vitro by PsAE treat-
ment, with the antitumoral effects demonstrated in allograft melanomas
after subcutaneous B16-F0 cells inoculation, the expression of cytostasis
and apoptosis related proteins were analyzed.
After 22 days of the melanoma induction, tumors of the animals orally
treated with 150 mg/day of PsAE were compared to the tumors resulting
from untreated animals (Figs. 7A and 7B). When the cell cycle arrest
related proteins were studied, p21 significantly increases (p ¼ 0.0133)
and PCNA did not diminish significantly in the PsAE treated group. The
apoptosis related protein cleaved PARP, was not detected in PsAE, nor in
Figure 4. Proliferation changes in B16-F0 cell line. A: Growth inhibition percentage (%) in a dose response MTT proliferation assay. B, C and D: Flow cytometric
analysis of cell division by dilution of CFSE. In B, CFSE representative histograms of control and treated cells (black line), pink solid histograms show undivided cells
(generation 0, G0) and purple histograms represent the following generations (G1 and G2). Panel C display Percentage (%) of cells distribution by generation in
different treatment paradigms. In D, tabular results and statistical comparison of cells distribution percentage (%) by generation, and mean/median fluorescence
intensity of total cells. CoNT ¼ Control No Treated; PsAE IC50 ¼ 2.44 μg/ml; PsAE LC50 ¼ 9.01; 5Fu IC50 ¼ 0.12 μg/ml and 5Fu LC50 ¼ 18.40 μg/ml. Treatments were
performed for 48 h. Results are expressed as mean  SEM, of three independent assays by triplicated and were compared by one-way ANOVA followed by Fisher LSD
test. *: indicate significant differences (p < 0.0001) respect to control group.
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lecular markers expression, it is possible to affirm that in vivo treatment
with oral PsAE exerts antitumoral actions by cytostasis, without
apoptosis mediated cell death. Moreover, in the used animal model in
which the treatment was orally administrated, the systemic PsAE should6
reach bioactivity levels that are comparable with the IC50 concentration
assayed in vitro.
As has been described in other natural compounds with systemic
antimelanoma actions, PsAE treatment may activate multiple target
pathways. Diverse compounds that induced G2/M cell cycle arrest
Figure 5. Cell cycle analysis of B16-F0 cells. A. Flow cytometric histograms show the DNA content and the corresponding percentages of cell cycle distribution in
control, IC50 and LC50 (0, 2.4 and 9 μg/ml, respectively) PsAE concentrations. B. Cell cycle distribution in bars. Cytometric analysis was performed after 24 h
treatment. Mean  SEM of 3 independent assays by triplicate are presented.
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soybeans), α-santalol (from Santalum album) and allyl-sulfides (obtained
from garlic), among others (Ravindranath et al., 2004; Wang et al., 2012;
Zhang and Dwivedi, 2011), have been reported. As PsAE, the mentioned
compounds were described to act by the control of proliferative signals,
altering cell cycle regulatory proteins and complexes, determining its
proved efficacy accompanied by null collateral effects. Moreover, the
multiple molecular targets involved, make able to explore and exploit the
synergistic combinations with other current available chemotherapeutic
agents, to promote the use of natural derived compounds as valuable
complementary treatments against cancer.
3. Conclusions
The present study demonstrates that the PsAE UHPLC fingerprint is
composed by phenolic compounds; which, at least 12 of them, were
previously reported as cytotoxic against cancer cells; supporting, at least
in part, the potential antitumoral activity of this plant. When PsAE is
orally administrated, prevents tumor progression in vivo by a significant
increase of the mice median survival with allograft colorectal tumors and
cause diminution of the tumor growth in subcutaneous B16-F0 induced
melanomas. The in vitro dose-response assays performed in this work
show that PsAE induces G2/M cell cycle arrest and apoptosis in B16-F0
cells, determining a significant over expression of the cyclin-dependent
kinase inhibitor p21cip1. Finally, the molecular study of the mice
induced melanomas indicates that systemic available plant derived
compounds cause cytostasis with over expression of p21cip1 but not
apoptosis. Altogether, the findings of the current work demonstrated the
antitumoral activity of PsAE when is orally administrated. Further
research are needed in order to explore its effect on the regulation of7
related signal pathways to support the plant extract use as complemen-
tary medicine for cancer treatment.
4. Materials and methods
4.1. Plant material and aqueous extract preparation
P. strombulifera was collected in February 2016 in 33 4401000 S, 68
210 30.500 W (Lavalle County, Mendoza, Argentina). Identified as MERL
61824 a voucher specimen is deposited in the Mendoza Ruiz Leal her-
barium. To obtain PsAE, leaves were autoclaved in distilled water, 50 g/
500 ml, for 1 h. After, solids separation by paper filtration, decoction was
boiled until volume reach 50 ml. Before use, crude extract was sterilized
by passing through a 0.22 μm pore size filter. The concentration (w/v)
was estimated by the ratio between the weight of the leaves, expressed in
grams, and the final volume obtained at the end of the preparation: 50 g/
50 ml ¼ 1 g/ml.
4.2. Detection and identification of PsAE compounds by UHPLC-Q-OT-
HESI-MS/MS
By UHPLC-Q-OT-HESI-MS/MS PsAE compounds were identified and
quantified. Collision and damping gas was performed by a Thermo Sci-
entific Dionex Ultimate 3000 UHPLC system (Thermo Fisher Scientific,
Germany), controlled by the Chromeleon 7.2 Software; hyphenated with
a Thermo high resolution Q Exactive focus mass spectrometer (Thermo,
Bremen, Germany). A Zefiro nitrogen generator (Clantecnologica, Sev-
illa, Spain) was used to obtain pure nitrogen (>99.999%). Equipment
calibration and parameters settings were performed as was previously
reported by Simirgiotis et al. (2016). The chromatography parameters
Figure 6. Western blot analysis of cultured B16-F0 cells. A. After 24 h, protein expression of control, IC50 and LC50 PsAE treated cells (0, 2.5 and 9 μg/ml, respectively)
are presented. B. Relative expression of p21, caspase 3, PCNA and cPARP with respect to TUBA1A are expressed in terms of mean  SEM of three assays by triplicated.
Results were compared by one-way ANOVA followed by Fisher LSD test. *: indicate significant differences (p  0.05) respect to control group. Full, non-adjusted
images of cPARP blot is provided in Supplementary Figure 1; TUBA1A (upper line) and PCNA (lower line) are provided in Supplementary Figure 2; caspase 3 is
provided in Supplementary Figure 3; and p21 is provided in Supplementary Figure 4.
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Corporation, Bellefonte, PA, USA), at 25 C. Detection settings were at
254, 280, 320, and 440 nm, and the PDA record was from 200 to 800 nm.
Mobile phases used were: (A) 1% formic acid aqueous solution and (B)
acetonitrile with 1% formic aqueous solution. The gradient program and
time (min, % of B) was: (0.00, 5); (5.00, 5); (10.00, 30); (15.00, 30);
(20.00, 70); (25.00, 70); (35.00, 5), and column equilibration for 12 min.
The injection volume was 10 μl and the flow rate fixed at 1 ml/min.
Samples and standards were dissolved in methanol and kept in the
autosampler at 10 C. TheMS parameters were as follows: the HESI II and
other parameters for the Q-orbitrap instrument were optimized as pre-
viously reported (Jimenez-Gonzalez et al., 2018).4.3. Animals and in vivo treatments
All animals were maintained in a controlled light (6:00 AM to 10:00
PM) and room temperature (22–24 C. Drinking liquids and mice chow
(Cargill, Argentina) were available ad libitum. In vivo treatment was
performed by diluting PsAE (150 mg/animal/day) in drinking water.
Intraperitoneal 5Fu was the chemotherapeutic control treatment
administrated, at 30 mg/kg/week, until animal sacrifice.
To study the animal median survival after DMH colorectal tumor
induction were used BALB/c males, 6 weeks old at the onset of treatment,
bred in our Institute. Four groups were separated of 10 animals each.
Group 1 was considered as survival control group and did not receive
treatments. In the other 3 groups was performed the colorectal tumor
induction by S.C. administration of DMH, 20 mg/kg/week, for 22 weeks
(Persia et al., 2017). In animals of group 2 (DMH), only tumoral induc-
tion was performed and mice were considered as no treated tumor sur-
vival group. In group 3 (DMH-PsAE), 8 weeks after tumor inductions
started, by dilution of PsAE in the drinking water, animals were treated at
the indicated dose. In group 4 (DMH-5Fu), 8 weeks after tumor in-
ductions started, animals receive 5Fu as described before. In the current8
experiment, the human endpoints to decide the animals’ euthanasia,
were: anal bleeding, anal tumor protrusion, reduction of spontaneous
activity, not eating/drinking, diarrhea, weight change more than 20 %,
no micturition and dyspnea.
To study PsAE effects in allograft melanoma tumors, 3 groups of 10
C57BL6wt males, bred in our Institute, 6 weeks old, were used. In all
groups, melanoma tumors were induced by subcutaneous inoculation of
1  105 B16-F0 (murine melanoma cancer cell line) in the right flank.
Group 1, did not receive any treatment after tumor cells inoculation;
groups 2 and 3, simultaneously with the tumor induction, animals
received PsAE and 5Fu as was described previously. The animals were
sacrificed at day 22 after cells inoculation. Then, developed tumors were
dissected, measured, weighted, stored at -80 C for immunobloting and
fixed for histology.
All procedures were approved by the Institutional Animal Care and
Use Committee of School of Medical Science, Universidad Nacional de
Cuyo (Protocol approval N 30/2014 and N 103/2017, respectively). All
animals in the protocols were cared in accordance with the Guiding
Principles in the Care and Use of Animals of the US National Institute of
Health.4.4. Cell culture and in vitro treatments
Because, there is not available commercial mice colorectal cancer cell
lines, the B16-F0 (ATCC, Virginia, EEUU) mice melanoma cell line was
selected to perform the in vitro studies and to correlate with the in vivo
findings. The cells were cultured as a monolayer in DMEM (Gibco, Grand
Island, NY, USA), containing 10 % v/v fetal bovine serum (Hyclone,
Canada), penicillin (100 IU/ml), streptomycin (100 μg/ml) and 3.7 mg/
ml NaHCO3. All cells were grown in a humidified atmosphere, containing
5% CO2 at 37 C. The treatments were dissolved in the culture media 24 h
after cell plating. The chemotherapeutic agent 5Fu (Filaxis®, Argentina)
was used as positive control at the indicated doses.
Figure 7. Western blot analysis of melanoma tumors. A. After 22 days of tumor induction, control and PsAE treated (150 mg/animal/day) groups are presented. B.
Relative expression of p21 and PCNA over TUBA1A are expressed in terms of mean  SEM. Results were compared by Student T test. *: indicates p ¼ 0.0296. Full, non-
adjusted images of p21 blot is provided in Supplementary Figure 5; TUBA1A (upper line) and PCNA (lower line) are provided in Supplementary Figure 6.
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To quantify proliferation and viability, trypan blue exclusion assay
was used in a dose-response experimental design. Briefly, 3  104 cells
were seeded into 6-well plates. After 24 h, media was replaced with fresh
culture media containing treatments at the indicated doses. After 48 h,
total cells were collected by trypsinization, incubated with trypan blue
and counted in a Neubauer haemocytometer chamber using a clear-field
microscopy. To assess the IC50 (concentration of treatment that induces
50% of growth inhibition) and the LC50, (concentration of treatment that
induces 50% of lethality), the total cell number and death cells were used
to statistically calculate the indexes (see below, point 2.11).4.6. MTT cell proliferation assay
The MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium
bromide)] is a colorimetric assay for assessing cell metabolic activity. It is
based on the cleavage of the yellow tetrazolium salt, MTT, to form a
soluble blue formazan product by mitochondrial enzymes, and the
amount of formazan produced is directly proportional to the number of
viable cells present. In 96-well microplates, 7 103/100 μl B16-F0 cells
were seeded; after 24 h, the medium was changed by fresh medium
containing PsAE or 5Fu (Filaxis®, Argentina) at indicated doses. 48 h
later, medium was replaced by MTT solution (0.5 mg/ml in DMEM,
without phenol red nor FBS, 100 μl/well). Then, plates were incubated
for an additional 4 h. After MTT solution was removed, 100 μl of DMSO
were added to dissolve the formazan crystals and shaken for 10 min. To
measure the optical density a Thermo Scientific Multiscan Elisa reader
was used at 570 nm. The optical density obtained in untreated control
cells (treatment concentration: 0 μg/ml) was considered as 100%9
viability; and the other values were calculated in accordance. The assay
was performed three times in triplicate.
4.7. Proliferative responses by CFSE dilution
For examining cells proliferative activity, a cell tracking dye carbox-
yfluorescein diacetate succinimidyl ester (CFDASE) was used. In the
labeled cells, the marker diffuses in the cytoplasm were present acetate
groups are cleaved to a CFSE, a fluorescent derivative which remains into
the cell. After mitosis, CFSE fluorescence intensity is divided in a half
with each generation and the number of rounds of cell division can be
visualized and quantified. Changes in CFSE fluorescence profile allows to
determine changes in cell division induced by any substance. Decreased
fluorescent intensity indicates higher proliferation rate; conversely, an
increased in fluorescence intensity indicates lower/null proliferation. In
the current assay, B16-F0 cells were stained with 5 μM of CFSE Cell
Tracer Kit (Invitrogen) for 5 min at 37 C. Then, labeled cells were
washed, quantified and seeded at 5 104 well into a 6-well plates. Treat-
ments at the indicated doses were performed for 48 h. Later, cells were
scraped and acquired in a FACS Aria III flow cytometer (BD Biosciences,
Mountain View, CA) and FlowJo.10 analysis software (Three star, US);
Flow Jo proliferation tool was setting as follows: #peaks 4.00; Fixed ratio
0.66; fixed CV: 10.1; fixed backgd: 1087.0. All experiments were per-
formed three times by triplicated.
4.8. Cell morphological analysis
Cells were seeded on cover-slides placed on the bottom of 6 well
plates at a density of 3  104 cells/well and grown overnight. The next
day, culture medium containing PsAE treatment was replaced at final
concentrations of 0, 2.4 and 9 μg/ml; which represent control, IC50 and
F.A. Persia et al. Heliyon 6 (2020) e03353LC50, respectively. After incubation for 48 h, the remaining cells were
fixed with methanol and stained with crystal violet solution. Coverslides
were then mounted, evaluated and photographed with a Nikon Eclipse
200 microscope.4.9. Cell cycle assay
Into a 6 well/plate, 5  104 cells/well were seeded and grown
overnight. Then, cells were treated with PsAE at 0 μg/ml, IC50 and LC50
concentrations, for 24 h. Later, cells were trypsinized, washed with PBS
and fixed in 4% paraformaldehide overnight. Then, fixed cells were
washed with PBS, incubated with 0.3 ml PBS containing 20 μg/ml RNase,
0.3 % IGEPAL, 1 mg/mL sodium citrate and 50 μg/ml of propidium io-
dide for 30 min at 37 C. The population at each stage of the cell cycle
was analyzed by flow cytometry, using a BD FACSaria III™ cytometer
(BD Biosciences, Mountain View, CA) and FlowJo.10 analysis software
(Three star, US).4.10. Protein expression by western blot analyses
To determine protein expression, cultured B16-F0 cells were analyzed
after 24 h of in vitro treatment. Melanomas generated in vivo by B16-F0
subcutaneous inoculation were also studied. Immunobloting was per-
formed as described previously (Hapon et al., 2014). To quantify and
statistically compares the protein expression, cultures were performed by
triplicated and three melanomas group were studied. Primary antibodies
used were: cyclin-dependent kinase inhibitor p21cip1 (Termofisher
AHZ0422), proliferating cell nuclear antigen (PCNA, Termofisher
MA511358), caspase 3 (Casp3, Invitrogen, 74T2), cleaved poly
(ADP-ribose) polymerase (cPARP, Termofisher 44698G), alpha tubulin
(TUBA1A, Termofisher 322500). Peroxidase conjugate secondary anti-
bodies used were: biotin conjugated antimouse and antirabbit (Jackson
115-035-003 and 711-065-152). Blots were developed using a ChemiDoc
XRS þ System (Bio-Rad, Laboratories) and band densitometric analysis
was performed using Image Lab Software version 4.0 from Bio-Rad
Laboratories.4.11. Statistical analysis
All data are expressed as mean  standard error (SEM) and analyzed
using GraphPad Prism 6.0 software. The animal survival curves were
performed by the Kaplan Meier analysis and compared using a Mantel
Cox test. To assess IC50 and LC50, was performed a sigmoidal dose-
response analysis and, when the goodness of fit showed R2  0.90,
values were considered acceptable. When two groups were compared,
the Student's T test was used; whereas, when more than two groups were
compared, one-way ANOVA followed by Fisher LSD test was used. In all
cases, statistical significance was considered when p  0.05.
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